ClinicalTrials.gg
CompletedNCT06621433Updated Oct 1, 2024

Titanium-prepared Platelet Rich Fibrin Versus Connective Tissue Graft for Management of Type-2 Gingival Recession

An interventional study of T-PRF with CAF and SECTG with CAF in Gingival Recession, sponsored by Rizk Beshir. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Rizk Beshir · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jan 2023, registered Sep 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of the study is to evaluate the effectiveness of using titanium prepared platelet rich fibrin with coronally advanced flap in the treatment of type-2 Cairo gingival recession.

02

Conditions studied

  • Gingival Recession

Browse trials for

03

In context

Gingival Recession

413 studies on the registry are indexed under Gingival Recession; 98 are open to participants now.

This study's enrollment of 44 is above the median of 30 across 379 interventional studies indexed under Gingival Recession.

Browse Gingival Recession studies →

Lead sponsor

This is the only study on the registry with Rizk Beshir as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gingival recession type 2 according to Cairo et al (2011).
  • Adequate amount of Attached Gingiva (AG) (2 mm≤ AG).
  • Good oral hygiene (full mouth bleeding score and O'Leary index less than ≤10 % after complete phase I therapy)
  • Clinically thick gingival biotype (1mm \< gingival thickness).
  • Anterior esthetic zone.

Exclusion criteria

Exclusion Criteria:

  • Patients with gingival recession types 1 and 3 according to Cairo et al.
  • Inadequate amount of attached gingiva (AG \< 2 mm).
  • Uncooperative patients.
  • Smoking more than 10 cigarettes per day.
  • Patients with known systemic conditions or taking medications that may affect soft tissue healing.
  • Pregnant and lactating women.
  • Patients with parafunctional habits.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Coronally advanced flap (CAF) in conjunction with titanium prepared PRF

    Other: T-PRF with CAF

  • Active comparator
    CAF in conjunction with subepithelial connective tissue graft (SECTG)

    Other: SECTG with CAF

Interventions

  • OtherT-PRF with CAF

    Blood sample will be obtained from the patient, conveyed into a titanium tube and immediately centrifuged at 2700 rpm for 12 mins at room temperature using fixed angle centrifuge (PRF Process, Tangkula800-1, China). The fibrin clot will be collected and placed in the PRF compression device (PRF GRF box) and condensed to produce a uniform T-PRF membrane which will be inserted over the recession area and covered by the coronally advanced flap.

  • OtherSECTG with CAF

    Sub epithelial connective tissue graft will be obtained from the donor site (hard palate), placed into recipient site and secured by sutures, then covered by a coronally advanced flap.

06

What researchers measure

Primary outcomes

  1. Probing depth

    The distance from the base of the pocket to the most apical point on the gingival margin will be measured using a periodontal probe.

    Time frame: up to 6 months

  2. Clinical attachment loss

    Distance from the cement-enamel junction to the base of the periodontal pocket will be measured using a periodontal probe

    Time frame: up to 6 months

  3. Recession width (RW)

    Recession width (W) measured at the widest point (it is the distance between the mesial gingival margin and the distal gingival margin of the tooth) using a periodontal probe

    Time frame: up to 6 months

  4. Recession height (RH)

    It will be measured from the cementoenamel junction to the Gingival Margin (GM), parallel to the long axis of the tooth starting from the most apical point of the recession using a William's graduated periodontal probe

    Time frame: up to 6 months

  5. Width of keratinized gingiva (KT)

    Width of keratinized gingiva will be measured as the distance from the gingival margin to the mucogingival junction

    Time frame: up to 6 months

07

Study locations

1 site
  • Faculty of Dentistry, Alexandria University
    Alexandria, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06621433
Lead sponsor
Rizk Beshir
Responsible party
Rizk Beshir (MSc. candidate of periodontology, Alexandria University) — Sponsor-investigator
First posted
Oct 1, 2024
Start date
Jan 1, 2023
Primary completion
Jan 20, 2024
Completion
Jan 22, 2024
Last update
Oct 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion